Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jul 11:12:131-140.
doi: 10.2147/TACG.S206745. eCollection 2019.

Pharmacogenetics of alcohol addiction: current perspectives

M S Zastrozhin  1   2 , V Yu Skryabin  1 , S S Miroshkin  1   2 , E A Bryun  1   2 , D A Sychev  1   2
Affiliations

Pharmacogenetics of alcohol addiction: current perspectives

M S Zastrozhin et al. Appl Clin Genet. .

Abstract

Genetics of alcohol addiction is currently a contradictive and complex field, where data in the most studies reflect methods' limitations rather than meaningful and complementary results. In our review, we focus on the genetics of alcohol addiction, leaving genetics of acute alcohol intoxication out of the scope. A review of the literature on pharmacogenetic biomarkers development for the pharmacotherapy personalization reveals that today the evidence base concerning these biomarkers is still insufficient. In particular, now the researches with the design of randomized controlled trials and meta-analysis investigating the effect of the SNPs as biomarkers on the therapy efficacy are available for naltrexone only. For other medications, there are only a few studies in small samples. It decreases the possibilities to implement the pharmacogenetic algorithms for the pharmacotherapy personalization in patients with alcohol use disorders (AUD). In view of the importance of the precision approaches development not in addiction medicine only, but in other fields of medicine also to increase the efficacy and safety of the therapy, studies on pharmacogenetic biomarkers development for the medications used in patients with AUD (eg, naltrexone, disulfiram, nalmefene, acamprosate, etc.) remain relevant to this day.

Keywords: acamprosate; alcohol use disorder; nalmefene; naltrexone; pharmacogenetics; pharmacogenomics.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest in this work.

Similar articles

See all similar articles

Cited by

References

    1. World Health Organization.Global Status Report on Alcohol and Health 2018. Geneva: World Health Organization; 2018. Licence: CC BY-NC-SA 3.0 IGO.
    1. Goldman D, Oroszi G, Ducci F. The genetics of addictions: uncovering the genes. Nat Rev Genet. 2005;6(7):521–532. doi:10.1038/nrg1635 - DOI - PubMed
    1. Enoch MA, Goldman D. The genetics of alcoholism and alcohol abuse. Curr Psychiatry Rep. 2001;3(2):144–151. - PubMed
    1. Ramoz N, Schumann G, Gorwood P. Genetic and pharmacogenetic aspects of alcohol-dependence. Curr Pharmacogenom. 2006;4(1):19–32. doi:10.2174/157016006776055383 - DOI
    1. Rinker JA, Mulholland PJ. Promising pharmacogenetic targets for treating alcohol use disorder: evidence from preclinical models. Pharmacogenomics. 2017;18(6):555–570. doi:10.2217/pgs-2016-0193 - DOI - PMC - PubMed